Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)-Reference-Cited by-同舟云学术

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

Published:2011-11-10 Issue:12 Volume:105 Page:1940-1948
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Schleiermacher G,Michon J,Ribeiro A,Pierron G,Mosseri V,Rubie H,Munzer C,Bénard J,Auger N,Combaret V,Janoueix-Lerosey I,Pearson A,Tweddle D A,Bown N,Gerrard M,Wheeler K,Noguera R,Villamon E,Cañete A,Castel V,Marques B,de Lacerda A,Tonini G P,Mazzocco K,Defferrari R,de Bernardi B,di Cataldo A,van Roy N,Brichard B,Ladenstein R,Ambros I,Ambros P,Beiske K,Delattre O,Couturier J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2011472.pdf

Reference35 articles.

1. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Benard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Potschger U, Ambros PF (2011) A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17: 792–804

2. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100: 1471–1482

3. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353: 2243–2253

4. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK (2010) Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363: 1313–1323

5. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kamshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger R, Tsuchida Y, Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 3-year-old child with multifocal (thoracoabdominal) primary neuroblastoma: A case report and literature review;Pediatric Hematology Oncology Journal;2024-09

2. Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531;Pediatric Blood & Cancer;2024-05-31

3. Neuroblastoma;Tata Memorial Centre Textbook of Oncology;2024

4. Epidemiology, Presentation, and Evaluation;Pediatric Oncology;2024

5. Use of Optical Genome Mapping to Detect Structural Variants in Neuroblastoma;Cancers;2023-10-31